Thus, tau protein has now emerged as a novel candidate to conduct further research regarding novel therapies for AD and the development of early detection biomarkers, two milestones required to promote AD prevention and the slowing of the onset of cognitive symptoms. The gene discussed is MAPT; the disease is Alzheimer disease.